Disc Medicine Reports $791M Cash Runway into 2029 and Key 2026 Pipeline Milestones

summarizeSummary

Disc Medicine announced a strong preliminary cash position of $791 million, providing a runway into 2029, alongside significant pipeline progress including the ongoing FDA priority review for bitopertin and multiple data readouts for other programs in 2026.

check_boxKey Events

• Strong Financial Position

  Preliminary unaudited cash, cash equivalents, and marketable securities totaled approximately $791 million as of December 31, 2025, providing a financial runway into 2029.

• Bitopertin Regulatory Update

  The New Drug Application (NDA) for bitopertin for Erythropoietic Protoporphyria (EPP) is under FDA priority review, with a decision anticipated in early 2026 following its Commissioner's National Priority Voucher (CNPV) designation.

• DISC-0974 Pipeline Progress

  Updated Phase 2 data for DISC-0974 in myelofibrosis (MF) anemia is expected in H2 2026, along with an End of Phase 2 meeting with the FDA and plans to initiate a Phase 2 study in anemia of inflammatory bowel disease (IBD).

• DISC-3405 Development Milestones

  Initial data from the ongoing Phase 2 study of DISC-3405 in polycythemia vera (PV) and Phase 1b study in sickle cell disease (SCD) are expected in H2 2026.

auto_awesomeAnalysis

This filing is highly significant for Disc Medicine, Inc., a clinical-stage biopharmaceutical company. The announcement of a preliminary unaudited cash, cash equivalents, and marketable securities balance of $791 million as of December 31, 2025, is a major positive, providing a financial runway into 2029. This substantially de-risks the company's operations and reduces the immediate need for dilutive financing. Furthermore, the company outlined a robust pipeline of upcoming catalysts for 2026, including the anticipated FDA approval and potential launch of bitopertin for EPP under priority review, which would mark its first commercial product. Key data readouts for DISC-0974 in myelofibrosis anemia and DISC-3405 in polycythemia vera and sickle cell disease are also expected in the second half of 2026. These combined financial and clinical updates provide strong validation for the company's strategy and future growth prospects.